AURA - NASDAQ

Aura Biosciences, Inc.

AURA·NASDAQ

$6.90

-0.29%

HealthcareBiotechnology

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$442.98M

EPS-1.7600

P/E Ratio-3.10

Earnings Date08/06/2026

aura

Total Other Income Expenses Net

Last Annual Value

6.71M

3-Year CAGR

64%

5-Year CAGR

10-Year CAGR

61%

Adjust for Inflation

Aura Biosciences, Inc. Competitors Analysis of Total Other Income Expenses Net

AURA · NASDAQ

Company	Total Other Income Expenses Net	CAGR 3Y	CAGR 5Y	CAGR 10Y
Aura Biosciences, Inc. NASDAQ:AURA	6.71M	-8.4%	N/A	N/A
Quantum-Si incorporated NASDAQ:QSI	-4.23M	N/A	N/A	N/A
Altimmune, Inc. NASDAQ:ALT	5.71M	-8.6%	N/A	102.8%
Design Therapeutics, Inc. NASDAQ:DSGN	9.68M	-5.1%	100.6%	N/A
Humacyte, Inc. NASDAQ:HUMA	66.60M	N/A	4.0%	N/A
Larimar Therapeutics, Inc. NASDAQ:LRMR	6.82M	12.4%	N/A	N/A
RAPT Therapeutics, Inc. NASDAQ:RAPT	6.24M	-15.3%	316.1%	N/A
Korro Bio, Inc. NASDAQ:KRRO	-29.28M	N/A	N/A	N/A
Annexon, Inc. NASDAQ:ANNX	9.72M	0.8%	90.2%	N/A
Solid Biosciences Inc. NASDAQ:SLDB	4.88M	-16.2%	136.5%	10.5%
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT	5.39M	-27.3%	N/A	N/A

Aura Biosciences, Inc. Fair Value Envelope

AURA · NASDAQ

Our analysis suggests that AURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $6.9, this represents a potential HIDDEN relative to our calculated worth for Aura Biosciences, Inc..

HIDDEN

Intrinsic Value

Current Price: $6.9

Related Guides

Blog Categories

Continue your AURA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.